<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232490</url>
  </required_header>
  <id_info>
    <org_study_id>Immunitor Hepko-V5</org_study_id>
    <secondary_id>IMM05</secondary_id>
    <nct_id>NCT02232490</nct_id>
  </id_info>
  <brief_title>Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L</brief_title>
  <acronym>Hepko-V5</acronym>
  <official_title>Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic
      benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular
      carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic
      benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular
      carcinoma. The results will be compared to placebo. The trial duration is 3 months and will
      consist of one stage with baseline laboratory evaluation including AFP levels with follow-up
      at monthly intervals. In addition pre-entry abdominal CT scan and end-study CT scan will be
      preformed. The clinical evaluation will be quantified according to special performance
      questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in plasma AFP</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in plasma AFP levels at monthly intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT scan</measure>
    <time_frame>3 months</time_frame>
    <description>changes in tumor size/mumber at 3 months compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse effects</measure>
    <time_frame>3 months</time_frame>
    <description>evaluation of adverse effects if any</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>HCC</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>hepcortespenlisimut-L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hepcortespenlisimut-L</intervention_name>
    <description>hepcortespenlisimut-L (V5) is given in experimental arm</description>
    <arm_group_label>hepcortespenlisimut-L</arm_group_label>
    <other_name>V5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who are at least 18 years old and are willing and capable of providing informed
        consent. Both men and non-pregnant women will be included.

        HCC diagnosis documented prior to Study Entry by either cytology/histology, CT scan, and
        AFP serum test higher or equal to 30 IU/ml.

        All subjects with reproductive potential are advised to utilize effective contraception
        throughout the course of this study.

        Health score status at baseline. Agreement to participate in the study and to give at least
        3 samples of blood for lab tests.

        Readily available home or o other address where patient can be found. -

        Exclusion Criteria:

        Subjects who might have already taken V5 in prior trials and have no baseline data. Those
        who met inclusion criteria can be retrospectively enrolled. Pregnant or breast-feeding
        women are excluded.

        Subjects who have taken other immunomodulatory therapies within 2 months prior to Entry:
        systemic corticosteroids, immune globulin (IV gamma globulin, IVIG), interferons,
        interleukins, pentoxifylline (Trental), thalidomide, filgrastim (G-CSF), sargramostim
        (GM-CSF); dinitrochlorobenzene (DNCB), thymosin alpha 1 (thymosin alpha), thymopentin,
        inosiplex (Isoprinosine), polyribonucleoside (Ampligen), ditiocarb sodium (Imuthiol), any
        locally available immune modulators, and any other therapeutic or preventive HCC vaccine.
        Subjects requiring concurrent participation in another experimental research treatment
        study, or who received an experimental agent within four weeks prior to Study Entry.

        Evidence of active or acute cardiac disease, epilepsy, or life-threatening diseases
        unrelated to HCC.

        Medical conditions such as active alcohol or substance abuse, or psychological issues that
        in the opinion of the local investigator would interfere with adherence to the requirements
        of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>aldar bourinbaiar</last_name>
    <role>Study Director</role>
    <affiliation>Immunitor LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldar Bourinbaiar, MD/PhD</last_name>
    <phone>+97695130306</phone>
    <email>immunitor@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Galyna kutsyna, MD</last_name>
    <phone>9053222</phone>
    <email>kutsynagalyna@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <zip>14400</zip>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aldar Bourinbaiar, MD</last_name>
      <phone>97688094463</phone>
      <email>immunitor@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <email>aldar@immunitor.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chinburen Jigjidsuren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <phone>97695130306</phone>
      <email>aldar@immunitor.com</email>
    </contact>
    <contact_backup>
      <last_name>Marina Tarakanovskaya, MD</last_name>
      <email>marinatarakanovskaya@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chinburen Jigjidsuren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <link>
    <url>http://www.prweb.com/releases/2014/06/prweb11965485.htm</url>
    <description>Interim Phase II trial outcome</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649454/</url>
    <description>Phase II results abstract</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Immunitor LLC</investigator_affiliation>
    <investigator_full_name>Aldar Bourinbaiar</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>AFP</keyword>
  <keyword>alpha-fetoprotein</keyword>
  <keyword>cancer vaccine</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>hepatitis</keyword>
  <keyword>HCC</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>liver tumor</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>DATA TO BE SHARED WITH COLLABORATORS</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

